U.S. Markets open in 34 hrs, 56 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,496.57 | 49.91 | 0.44% |
| NASDAQ | 2,282.78 | -29.52 | -1.28% |
| S&P 500 | 1,260.68 | 0.36 | 0.03% |
| Day Low 09:35 AM EDT | 1.59 | |
|---|---|---|
| Day High 01:04 PM EDT | 1.71 |
|
| Range | 0.12 | |
| Volume | 21,574 | |
| 30-Day Avg. Vol. | 19,000 |
|
| Difference | 13.55% | |
| Market Cap. | 33.99 M | |
| Change | 2.88 M | |
| Shares Out. | 20.83 M | |
| Percent Traded | 0.10% | |
| Revenue | 31.65 M | |
| Earnings | -2.75 M | |
| EPS (TTM) | -0.24001 |
| 52-Wk Low 7/15/08 | 1.12 | |
|---|---|---|
| 52-Wk High 7/18/07 | 3.14 |
|
| Range | 2.02 | |
| Prev. Close 7/17/08 | 1.51 | |
| Today's Open | 1.59 | |
| Change | 5.30% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.6233 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | — |
Encorium Group (formerly Covalent) has some strong bonds with its clients. The contract research organization (CRO) manages all stages of clinical trials for pharmaceutical, biotech, and medical device ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | — — | — — |
—
—
|
| Last Quarter | — — | — — |
—
—
|
| Quarterly - 03/31/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 8.59 M | 31.65 M |
| Gross Profit | 2.40 M | 8.80 M |
| Operating Income | -2.17 M | -3.57 M |
| Net Income | -2.01 M | -2.75 M |
Real-Time Quote
